PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune resp...
Saved in:
| Published in | The oncologist (Dayton, Ohio) Vol. 24; no. S1; pp. S31 - S41 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, USA
John Wiley & Sons, Inc
01.02.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD‐1)/programmed cell death protein ligand 1 (PD‐L1) axis leading to the exhaustion of T‐cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD‐1 or PD‐L1 have been developed and approved for the treatment of various advanced cancers, including non‐small‐cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD‐1/PD‐L1 blockade therapy significantly improves the durable response rate and prolongs long‐term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment‐related adverse effects. In this article, we summarize the latest clinical applications of PD‐1/PD‐L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD‐1/PD‐L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside‐to‐bench studies in cancer immunotherapy as well.
Implications for Practice
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD‐1) and programmed cell death protein ligand 1 (PD‐L1) display apparent benefits for the treatment of advanced non‐small‐cell lung cancer (NSCLC). However, the clinical applications of these therapies are challenged by the limited benefit population with additional high economic burden and adverse events. This review discusses the bottlenecks of ICI therapy in clinical practice and provides appropriate guidance in the development of predictive biomarkers, the establishment of the criteria for combining PD‐1/PD‐L1 blockade therapy with the existing therapies, and the management of adverse events observed both in monotherapy and combination therapy, which will help maximize the applications of ICIs in advanced NSCLC.
摘要
免疫检查点抑制剂 (ICI) 的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同，ICI 可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中，已经广泛研究了导致慢性感染和肿瘤中 T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 (PD‐L1) 轴。因此，已经开发了靶向 PD‐1 或 PD‐L1 的阻断抗体，并批准用于治疗各种晚期癌症，包括非小细胞肺癌 (NSCLC)，这使其成为最成功的 ICI。在晚期 NSCLC，与化疗或放疗相比，PD‐1/PD‐L1 阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存，而且不良反应很少。然而，对于进一步的临床应用却存在大量挑战，例如，仅有小部分群体受益，存在原发性和获得性耐药，缺乏预测和预后生物标志物，以及存在治疗相关不良反应。在本文中，我们总结了中国及全球范围内 PD‐1/PD‐L1 阻断治疗在晚期 NSCLC 中的最新临床应用，并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC 中的应用，同时，也将促进癌症免疫治疗“从临床到实验室”的研究。
实践意义:在晚期非小细胞肺癌 (NSCLC) 的治疗中，靶向程序性细胞死亡蛋白 1 (PD‐1) 和程序性细胞死亡蛋白配体 1 (PD‐L1) 的免疫检查点抑制剂 (ICI) 呈现出明显益处。然而，这些治疗的临床应用却面临着受益群体有限、额外的高昂经济负担和不良事件等挑战。本篇综述讨论了 ICI 疗法在临床实践中的瓶颈，并为预测生物标志物的形成、将 PD‐1/PD‐L1 阻断治疗与现有治疗相结合的标准确立、以及在单药和联合治疗中观察到的不良事件的管理提供了适当的指导，从而有助于最大化 ICI 在晚期 NSCLC 中的应用。
This article summarizes the latest clinical applications of PD‐1/PD‐L1 blockade therapy in advanced non‐small cell lung cancer (NSCLC) worldwide and in China, reporting the bottlenecks related to the use of this therapy in clinic. An exploration of the underlying mechanism of PD‐1/PD‐L1 blockade therapy and biomarker identification will maximize the application of immune checkpoint inhibitors in advanced NSCLC and facilitate bedside‐to‐bench studies in cancer immunotherapy. |
|---|---|
| AbstractList | The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD‐1)/programmed cell death protein ligand 1 (PD‐L1) axis leading to the exhaustion of T‐cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD‐1 or PD‐L1 have been developed and approved for the treatment of various advanced cancers, including non‐small‐cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD‐1/PD‐L1 blockade therapy significantly improves the durable response rate and prolongs long‐term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment‐related adverse effects. In this article, we summarize the latest clinical applications of PD‐1/PD‐L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD‐1/PD‐L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside‐to‐bench studies in cancer immunotherapy as well.
Implications for Practice
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD‐1) and programmed cell death protein ligand 1 (PD‐L1) display apparent benefits for the treatment of advanced non‐small‐cell lung cancer (NSCLC). However, the clinical applications of these therapies are challenged by the limited benefit population with additional high economic burden and adverse events. This review discusses the bottlenecks of ICI therapy in clinical practice and provides appropriate guidance in the development of predictive biomarkers, the establishment of the criteria for combining PD‐1/PD‐L1 blockade therapy with the existing therapies, and the management of adverse events observed both in monotherapy and combination therapy, which will help maximize the applications of ICIs in advanced NSCLC.
摘要
免疫检查点抑制剂 (ICI) 的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同，ICI 可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中，已经广泛研究了导致慢性感染和肿瘤中 T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 (PD‐L1) 轴。因此，已经开发了靶向 PD‐1 或 PD‐L1 的阻断抗体，并批准用于治疗各种晚期癌症，包括非小细胞肺癌 (NSCLC)，这使其成为最成功的 ICI。在晚期 NSCLC，与化疗或放疗相比，PD‐1/PD‐L1 阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存，而且不良反应很少。然而，对于进一步的临床应用却存在大量挑战，例如，仅有小部分群体受益，存在原发性和获得性耐药，缺乏预测和预后生物标志物，以及存在治疗相关不良反应。在本文中，我们总结了中国及全球范围内 PD‐1/PD‐L1 阻断治疗在晚期 NSCLC 中的最新临床应用，并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC 中的应用，同时，也将促进癌症免疫治疗“从临床到实验室”的研究。
实践意义:在晚期非小细胞肺癌 (NSCLC) 的治疗中，靶向程序性细胞死亡蛋白 1 (PD‐1) 和程序性细胞死亡蛋白配体 1 (PD‐L1) 的免疫检查点抑制剂 (ICI) 呈现出明显益处。然而，这些治疗的临床应用却面临着受益群体有限、额外的高昂经济负担和不良事件等挑战。本篇综述讨论了 ICI 疗法在临床实践中的瓶颈，并为预测生物标志物的形成、将 PD‐1/PD‐L1 阻断治疗与现有治疗相结合的标准确立、以及在单药和联合治疗中观察到的不良事件的管理提供了适当的指导，从而有助于最大化 ICI 在晚期 NSCLC 中的应用。
This article summarizes the latest clinical applications of PD‐1/PD‐L1 blockade therapy in advanced non‐small cell lung cancer (NSCLC) worldwide and in China, reporting the bottlenecks related to the use of this therapy in clinic. An exploration of the underlying mechanism of PD‐1/PD‐L1 blockade therapy and biomarker identification will maximize the application of immune checkpoint inhibitors in advanced NSCLC and facilitate bedside‐to‐bench studies in cancer immunotherapy. This article summarizes the latest clinical applications of PD‐1/PD‐L1 blockade therapy in advanced non‐small cell lung cancer (NSCLC) worldwide and in China, reporting the bottlenecks related to the use of this therapy in clinic. An exploration of the underlying mechanism of PD‐1/PD‐L1 blockade therapy and biomarker identification will maximize the application of immune checkpoint inhibitors in advanced NSCLC and facilitate bedside‐to‐bench studies in cancer immunotherapy. The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis leading to the exhaustion of T-cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD-1 or PD-L1 have been developed and approved for the treatment of various advanced cancers, including non-small-cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD-1/PD-L1 blockade therapy significantly improves the durable response rate and prolongs long-term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment-related adverse effects. In this article, we summarize the latest clinical applications of PD-1/PD-L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD-1/PD-L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside-to-bench studies in cancer immunotherapy as well. IMPLICATIONS FOR PRACTICE: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) display apparent benefits for the treatment of advanced non-small-cell lung cancer (NSCLC). However, the clinical applications of these therapies are challenged by the limited benefit population with additional high economic burden and adverse events. This review discusses the bottlenecks of ICI therapy in clinical practice and provides appropriate guidance in the development of predictive biomarkers, the establishment of the criteria for combining PD-1/PD-L1 blockade therapy with the existing therapies, and the management of adverse events observed both in monotherapy and combination therapy, which will help maximize the applications of ICIs in advanced NSCLC. The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis leading to the exhaustion of T-cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD-1 or PD-L1 have been developed and approved for the treatment of various advanced cancers, including non-small-cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD-1/PD-L1 blockade therapy significantly improves the durable response rate and prolongs long-term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment-related adverse effects. In this article, we summarize the latest clinical applications of PD-1/PD-L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD-1/PD-L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside-to-bench studies in cancer immunotherapy as well. IMPLICATIONS FOR PRACTICE: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) display apparent benefits for the treatment of advanced non-small-cell lung cancer (NSCLC). However, the clinical applications of these therapies are challenged by the limited benefit population with additional high economic burden and adverse events. This review discusses the bottlenecks of ICI therapy in clinical practice and provides appropriate guidance in the development of predictive biomarkers, the establishment of the criteria for combining PD-1/PD-L1 blockade therapy with the existing therapies, and the management of adverse events observed both in monotherapy and combination therapy, which will help maximize the applications of ICIs in advanced NSCLC.The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis leading to the exhaustion of T-cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD-1 or PD-L1 have been developed and approved for the treatment of various advanced cancers, including non-small-cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD-1/PD-L1 blockade therapy significantly improves the durable response rate and prolongs long-term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment-related adverse effects. In this article, we summarize the latest clinical applications of PD-1/PD-L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD-1/PD-L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside-to-bench studies in cancer immunotherapy as well. IMPLICATIONS FOR PRACTICE: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) display apparent benefits for the treatment of advanced non-small-cell lung cancer (NSCLC). However, the clinical applications of these therapies are challenged by the limited benefit population with additional high economic burden and adverse events. This review discusses the bottlenecks of ICI therapy in clinical practice and provides appropriate guidance in the development of predictive biomarkers, the establishment of the criteria for combining PD-1/PD-L1 blockade therapy with the existing therapies, and the management of adverse events observed both in monotherapy and combination therapy, which will help maximize the applications of ICIs in advanced NSCLC. |
| Author | Liu, Yuanyong Xia, Liliang Wang, Ying |
| Author_xml | – sequence: 1 givenname: Liliang surname: Xia fullname: Xia, Liliang organization: Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiaotong University School of Medicine – sequence: 2 givenname: Yuanyong surname: Liu fullname: Liu, Yuanyong organization: School of Life Science and Technology, Changchun University of Science and Technology – sequence: 3 givenname: Ying surname: Wang fullname: Wang, Ying email: ywang@sibs.ac.cn organization: Shanghai‐MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30819829$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUU1vEzEQtVAR_YC_gHzgwGVbe73eD4SQ2i1tI0VdpBSJm-XYk8Tg2Km9W5QbP4HfyC_BS0pFOcFpRjNv3puZd4j2nHeA0CtKjmnJipN-Bd4pb_3SxP44J7TJJl02o1kk_Ak6oLxosqIhn_ZSTmqWVZQ3--gwxs-EpJTlz9A-IzVt6rw5QJsP5z--facnv8KU4jPr1RepAd-sIMjNFhuHT_WddAo0vvYuoWZraW2KLViLp4Nb4nZshze4HUIA1-NZL_shYuk0vhj6IQA-NwFUb7yLz9HThbQRXtzHI_Tx4v1Ne5VNu8tJezrNFCcFyZQmFZVaKZJLVpW6BAm0GSuyBK5UOoRyqUu2KKBhfM5IxRWpYTEnNed5wY7Qux3vZpivQau0V5BWbIJZy7AVXhrxuOPMSiz9nShZU1RVnghe3xMEfztA7MXaRJVulg78EEVO64pTVvNR6-WfWg8iv9-cAG93ABV8jAEWDxBKxOiqeOSqGF0Vk07MqEiupvGzv8aVSS9O70ybG_uvJO2O5KuxsP2vBUR33XY0r0rCfgLnrM2i |
| CitedBy_id | crossref_primary_10_3389_fimmu_2025_1521362 crossref_primary_10_1080_1120009X_2023_2294582 crossref_primary_10_1016_j_intimp_2024_111799 crossref_primary_10_3389_fimmu_2022_964442 crossref_primary_10_1186_s12957_020_02070_9 crossref_primary_10_1186_s40001_023_01581_x crossref_primary_10_14336_AD_2024_0546 crossref_primary_10_1007_s12094_023_03187_5 crossref_primary_10_3389_fimmu_2021_756872 crossref_primary_10_1097_MD_0000000000025157 crossref_primary_10_1097_MD_0000000000026367 crossref_primary_10_1080_15384047_2024_2392902 crossref_primary_10_3390_ijerph19159265 crossref_primary_10_1007_s40487_021_00171_3 crossref_primary_10_3389_fpubh_2022_1015702 crossref_primary_10_3390_pharmaceutics15071788 crossref_primary_10_1016_j_critrevonc_2024_104288 crossref_primary_10_1016_j_humimm_2024_111105 crossref_primary_10_3390_s24010037 crossref_primary_10_1016_j_intimp_2022_108813 crossref_primary_10_1016_j_lungcan_2021_08_006 crossref_primary_10_1002_mc_23740 crossref_primary_10_3389_fphar_2023_1026135 crossref_primary_10_1016_j_molimm_2022_12_008 crossref_primary_10_3389_fonc_2022_911579 crossref_primary_10_3171_2021_2_FOCUS201067 crossref_primary_10_3389_fimmu_2024_1420463 crossref_primary_10_3390_ijms241311179 crossref_primary_10_1093_abbs_gmaa036 crossref_primary_10_1158_1535_7163_MCT_20_0934 crossref_primary_10_1186_s12938_022_00987_8 crossref_primary_10_1186_s12951_021_01094_x crossref_primary_10_3389_fimmu_2024_1482746 crossref_primary_10_3389_fphar_2021_687399 crossref_primary_10_3892_or_2023_8651 crossref_primary_10_2147_PGPM_S332683 crossref_primary_10_3389_fonc_2021_757993 crossref_primary_10_2217_imt_2022_0257 crossref_primary_10_4081_ejh_2023_3784 crossref_primary_10_1017_erm_2022_9 crossref_primary_10_1093_cid_ciaa802 crossref_primary_10_3390_biomedicines10123277 crossref_primary_10_3892_ol_2024_14334 crossref_primary_10_1080_26895293_2022_2085814 crossref_primary_10_3390_ijms24021506 crossref_primary_10_1007_s00108_023_01652_5 crossref_primary_10_1159_000510103 crossref_primary_10_2147_CMAR_S461964 crossref_primary_10_1186_s13046_024_03122_8 crossref_primary_10_1016_j_prp_2024_155104 crossref_primary_10_1002_psp4_12917 crossref_primary_10_1007_s10528_023_10641_0 crossref_primary_10_3389_fimmu_2023_1173524 crossref_primary_10_1016_j_pdpdt_2024_104427 crossref_primary_10_1111_1759_7714_14180 crossref_primary_10_3389_fphar_2021_781425 crossref_primary_10_1620_tjem_2023_J014 crossref_primary_10_1002_cam4_4197 crossref_primary_10_1016_j_canlet_2022_216020 crossref_primary_10_12677_ACM_2023_1361469 crossref_primary_10_18632_aging_204601 crossref_primary_10_1016_j_intimp_2022_108955 crossref_primary_10_1016_j_lungcan_2021_01_018 crossref_primary_10_1016_j_intimp_2020_106295 crossref_primary_10_1016_j_ymthe_2023_09_015 crossref_primary_10_1136_jitc_2023_006788 crossref_primary_10_3389_fphar_2022_1037620 crossref_primary_10_1016_j_ejps_2023_106516 crossref_primary_10_12677_ACM_2023_1351154 crossref_primary_10_1016_j_lungcan_2023_02_009 crossref_primary_10_1186_s12885_023_11285_4 crossref_primary_10_3892_ijo_2022_5302 crossref_primary_10_1016_j_clon_2023_07_012 crossref_primary_10_3389_fonc_2021_699847 crossref_primary_10_3389_fonc_2022_1012561 crossref_primary_10_3390_cells9091964 crossref_primary_10_3892_mco_2024_2798 crossref_primary_10_3390_cancers14194761 crossref_primary_10_3389_fonc_2021_626984 crossref_primary_10_1002_advs_202309697 crossref_primary_10_3389_fphar_2025_1485661 crossref_primary_10_1155_2022_9942918 crossref_primary_10_1016_j_intimp_2023_110038 crossref_primary_10_3390_cancers17060994 crossref_primary_10_1016_j_clcc_2023_03_001 crossref_primary_10_3389_fonc_2023_1077675 crossref_primary_10_21518_2079_701X_2020_9_258_264 crossref_primary_10_3389_fimmu_2023_1278011 crossref_primary_10_3389_fonc_2022_874823 crossref_primary_10_3389_fimmu_2022_912180 crossref_primary_10_1016_j_humpath_2020_10_014 crossref_primary_10_1007_s11427_020_1861_5 crossref_primary_10_1007_s00262_023_03434_2 crossref_primary_10_3389_fonc_2021_591106 crossref_primary_10_3389_fimmu_2022_1012247 crossref_primary_10_1007_s00262_024_03893_1 crossref_primary_10_1155_2022_4022896 crossref_primary_10_1080_10717544_2021_1927246 crossref_primary_10_1097_DSS_0000000000002850 crossref_primary_10_2147_CMAR_S272603 crossref_primary_10_1136_jitc_2021_004113 crossref_primary_10_1177_03936155241310887 crossref_primary_10_1007_s12325_024_02808_x crossref_primary_10_1002_ctm2_1101 crossref_primary_10_3389_fonc_2021_621050 crossref_primary_10_3389_fpubh_2021_743558 crossref_primary_10_3892_ol_2020_11508 crossref_primary_10_1016_j_lungcan_2021_05_031 crossref_primary_10_3389_fmed_2022_894338 crossref_primary_10_1038_s41419_021_04033_8 crossref_primary_10_3389_fonc_2022_809304 crossref_primary_10_1016_j_ccmp_2021_100005 crossref_primary_10_1039_D2DT00944G crossref_primary_10_1177_14604582221102314 crossref_primary_10_3389_fimmu_2022_1047610 crossref_primary_10_3389_fimmu_2021_683332 crossref_primary_10_3390_ijms24065626 crossref_primary_10_3389_fmicb_2021_707290 crossref_primary_10_3389_fonc_2023_1145128 crossref_primary_10_3390_cancers16233996 crossref_primary_10_1007_s12094_023_03337_9 crossref_primary_10_7759_cureus_52720 crossref_primary_10_3892_ol_2024_14277 crossref_primary_10_3389_fimmu_2021_762120 crossref_primary_10_12677_ACM_2024_142617 crossref_primary_10_1111_odi_15276 crossref_primary_10_1038_s41419_025_07505_3 crossref_primary_10_1002_cam4_4338 crossref_primary_10_3390_ijms22126246 crossref_primary_10_1186_s12885_021_08006_0 crossref_primary_10_1097_MPA_0000000000002419 crossref_primary_10_1007_s12094_021_02588_8 crossref_primary_10_2174_0109298673293174240320053546 crossref_primary_10_3390_ijms222010955 crossref_primary_10_2174_1871520622666220827125929 crossref_primary_10_3389_fimmu_2023_1278573 crossref_primary_10_3389_fonc_2021_635007 crossref_primary_10_3389_fmed_2024_1349178 crossref_primary_10_1186_s12967_023_04073_y crossref_primary_10_1007_s00520_025_09308_w crossref_primary_10_1080_1061186X_2024_2445772 crossref_primary_10_1002_cam4_7175 crossref_primary_10_1088_2057_1976_ac4d43 crossref_primary_10_3390_ijms22179125 crossref_primary_10_1186_s13045_020_01024_8 crossref_primary_10_1089_gtmb_2022_0004 crossref_primary_10_3389_fimmu_2022_813072 crossref_primary_10_1038_s41392_024_01771_x crossref_primary_10_1080_0886022X_2023_2238823 crossref_primary_10_3390_jpm11030179 crossref_primary_10_1016_j_gpb_2022_11_003 crossref_primary_10_2147_OTT_S255491 crossref_primary_10_1016_j_archoralbio_2020_104916 crossref_primary_10_1136_jitc_2022_006234 crossref_primary_10_1007_s13353_023_00786_4 crossref_primary_10_1016_j_tranon_2021_101148 crossref_primary_10_1155_2022_3601942 crossref_primary_10_1002_hed_27340 crossref_primary_10_3389_fimmu_2023_1274547 crossref_primary_10_1007_s00109_025_02531_2 crossref_primary_10_1007_s00432_021_03845_7 crossref_primary_10_1016_j_intimp_2020_106214 crossref_primary_10_1186_s13045_022_01325_0 crossref_primary_10_3389_fonc_2021_639168 crossref_primary_10_3389_fimmu_2021_696749 crossref_primary_10_1186_s12885_022_09470_y crossref_primary_10_1093_jjco_hyae058 crossref_primary_10_1016_j_bbrc_2023_149344 crossref_primary_10_2217_cer_2020_0053 crossref_primary_10_3389_fonc_2023_1092663 crossref_primary_10_1016_j_intimp_2022_109031 crossref_primary_10_4236_abb_2023_144010 crossref_primary_10_1016_j_prp_2023_154625 crossref_primary_10_2174_0113816128330530240918073721 crossref_primary_10_1186_s40644_025_00826_8 crossref_primary_10_3389_fonc_2022_858756 crossref_primary_10_1177_20406223231189224 crossref_primary_10_3390_cancers14010122 crossref_primary_10_1016_j_lungcan_2023_107353 crossref_primary_10_1186_s13045_021_01161_8 crossref_primary_10_1038_s41419_023_06376_w crossref_primary_10_3389_fphar_2023_1330877 crossref_primary_10_3389_fimmu_2023_1227797 crossref_primary_10_62347_MVRG3697 crossref_primary_10_1001_jamanetworkopen_2022_4637 crossref_primary_10_1016_j_neo_2023_100923 crossref_primary_10_1186_s12935_020_01481_8 crossref_primary_10_1016_j_molimm_2020_12_020 crossref_primary_10_2217_imt_2023_0008 crossref_primary_10_1007_s12282_022_01344_2 crossref_primary_10_1016_j_omto_2021_05_005 crossref_primary_10_1021_acs_jmedchem_4c00568 crossref_primary_10_1016_j_intimp_2024_112152 crossref_primary_10_1007_s00432_022_04080_4 crossref_primary_10_1186_s40644_024_00779_4 crossref_primary_10_1186_s12885_023_10836_z crossref_primary_10_1080_14737167_2023_2144837 crossref_primary_10_1111_1759_7714_14436 crossref_primary_10_3390_cancers12010040 crossref_primary_10_1016_j_tranon_2024_102082 crossref_primary_10_3389_fcell_2022_851032 crossref_primary_10_3389_fonc_2024_1283008 crossref_primary_10_2147_CMAR_S333416 crossref_primary_10_3389_fonc_2023_1137913 crossref_primary_10_1016_j_jtocrr_2022_100324 crossref_primary_10_1111_prd_12548 crossref_primary_10_3389_fimmu_2022_1026214 crossref_primary_10_3390_life11111235 crossref_primary_10_1016_j_omto_2020_03_021 crossref_primary_10_1097_MD_0000000000021613 crossref_primary_10_4103_jcrt_jcrt_855_21 crossref_primary_10_1155_2021_9965371 crossref_primary_10_1155_2022_8447083 crossref_primary_10_3389_fimmu_2024_1366260 crossref_primary_10_1002_cac2_12609 crossref_primary_10_3390_cancers16101896 crossref_primary_10_1016_j_cpt_2025_02_007 crossref_primary_10_1016_j_jtho_2023_03_008 crossref_primary_10_1038_s41598_023_38117_6 crossref_primary_10_3389_fonc_2022_898964 crossref_primary_10_2217_imt_2021_0196 crossref_primary_10_3390_cancers16183222 crossref_primary_10_1073_pnas_2120956119 crossref_primary_10_2217_imt_2023_0147 crossref_primary_10_1016_j_cytogfr_2022_07_004 crossref_primary_10_3390_ijms222111302 crossref_primary_10_3390_jnt5020003 crossref_primary_10_1126_sciadv_abc8346 crossref_primary_10_1155_2022_4664651 crossref_primary_10_3390_cancers13081788 crossref_primary_10_1002_cam4_70143 crossref_primary_10_2174_0113862073267261231106093845 crossref_primary_10_3389_fonc_2022_958043 crossref_primary_10_7554_eLife_73699 crossref_primary_10_1016_j_ejca_2020_03_033 crossref_primary_10_1186_s13046_023_02753_7 crossref_primary_10_1016_j_gene_2022_146325 crossref_primary_10_1097_PAI_0000000000000999 crossref_primary_10_1177_10732748231155700 crossref_primary_10_3390_ijms25042323 crossref_primary_10_1186_s40164_024_00570_y crossref_primary_10_1002_ctm2_718 crossref_primary_10_2217_bmm_2023_0195 |
| Cites_doi | 10.1002/ijc.29210 10.1016/j.jtho.2017.08.022 10.1016/S1470-2045(18)30144-X 10.1186/s13045-017-0541-9 10.1634/theoncologist.2017-0229 10.1016/j.jtho.2017.01.019 10.1038/70932 10.1126/science.271.5256.1734 10.1016/j.critrevonc.2016.02.001 10.1038/nm.4466 10.1038/nature22396 10.1056/NEJMoa1606774 10.1038/s41591-018-0057-z 10.1038/nature22079 10.21037/jtd.2018.01.109 10.1016/j.coi.2015.01.006 10.1038/nature04444 10.1093/annonc/mdx212 10.1056/NEJMoa1200694 10.3390/ijms17050790 10.1084/jem.20100643 10.1002/1878-0261.12029 10.1093/annonc/mdx190 10.1126/science.aaf1292 10.1136/esmoopen-2017-000236 10.1158/1078-0432.CCR-15-3101 10.1186/s13045-017-0506-z 10.1126/science.aaf2834 10.1084/jem.176.6.1595 10.1056/NEJMoa1716948 10.1186/s12916-016-0705-4 10.1158/0008-5472.CAN-15-0255 10.1038/nm730 10.1056/NEJMoa1504627 10.1126/science.aaf0683 10.1158/1538-7445.AM2018-CT114 10.1084/jem.182.2.459 10.3322/caac.21208 10.1016/S0140-6736(15)01281-7 10.1159/000438523 10.1016/j.neo.2017.08.004 10.1084/jem.183.6.2533 10.1126/scitranslmed.3006504 10.1634/theoncologist.2015-0498 10.1634/theoncologist.2015-0507 10.1200/JCO.2018.36.15_suppl.105 10.1016/j.lungcan.2017.01.013 10.1146/annurev.immunol.26.021607.090331 10.2217/imt-2016-0150 10.2217/imt.15.84 10.1038/s41591-018-0085-8 10.1056/NEJMoa1709937 10.1038/nature10673 10.1016/S1470-2045(15)00544-6 10.1016/j.maturitas.2009.12.012 10.1016/S1470-2045(16)30498-3 10.1007/s40265-017-0749-6 10.1089/cbr.1994.9.183 10.1080/14737159.2017.1398083 10.1056/NEJMoa0904554 10.1126/science.aan3706 10.1093/jnci/85.8.622 10.1634/theoncologist.2017-0087 10.1634/theoncologist.2017-0078 10.1634/theoncologist.2017-0004 10.1093/intimm/dxm057 10.1093/jnci/86.15.1159 10.1634/theoncologist.2016-0496 10.1200/JCO.2018.36.18_suppl.LBA4 10.1111/imr.12519 10.1056/NEJMoa1613493 10.1200/JCO.2016.71.9476 10.1126/science.aan4236 10.1056/NEJMoa1716078 10.1016/S1470-2045(16)30624-6 10.1158/1078-0432.CCR-10-3126 10.1038/328267a0 10.1038/nature24462 10.1016/j.cell.2017.07.024 10.1084/jem.20112741 10.1080/2162402X.2016.1213934 10.1016/S0140-6736(16)00587-0 10.1093/jnci/djv069 10.1634/theoncologist.2016-0476 10.1056/NEJMoa1507643 10.1200/JCO.2017.74.3062 10.1016/j.cell.2017.05.005 10.1056/NEJMoa1801005 10.1200/JCO.2014.60.0130 10.1038/nature24473 10.1056/NEJMoa1801946 10.1002/j.1460-2075.1992.tb05481.x 10.1084/jem.192.7.1027 10.1097/JTO.0000000000000033 10.1016/S1470-2045(17)30512-0 10.1016/S1556-0864(16)30301-X 10.1172/jci.insight.93397 10.1016/S0140-6736(16)32517-X 10.3389/fmicb.2017.01162 10.1126/science.aaa1348 10.1038/nbt.4180 10.1016/S1470-2045(17)30422-9 10.1056/NEJMoa1003466 10.1158/1535-7163.MCT-17-0386 10.1126/science.aaf1490 10.1016/j.cllc.2016.06.006 10.1200/JCO.2010.32.6181 10.3322/caac.21338 10.1073/pnas.1705327114 10.2217/imt-2017-0121 10.1016/j.cllc.2016.03.003 10.1200/JCO.2018.36.18_suppl.LBA9000 |
| ContentType | Journal Article |
| Copyright | AlphaMed Press 2019 AlphaMed Press 2019. |
| Copyright_xml | – notice: AlphaMed Press 2019 – notice: AlphaMed Press 2019. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1634/theoncologist.2019-IO-S1-s05 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-490X |
| EndPage | S41 |
| ExternalDocumentID | PMC6394772 30819829 10_1634_theoncologist_2019_IO_S1_s05 ONCO12760 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 0R~ 123 18M 1OC 2WC 36B 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAMMB AAPXW AAVAP AAWTL AAZKR ABEJV ABGNP ABPTD ABUWG ABXVV ACXQS ADBBV ADXAS AEFGJ AEGXH AENEX AFKRA AFPKN AGXDD AIDQK AIDYY AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BENPR BFHJK CCPQU CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO IHR INH ITC LUTES LYRES M1P O9- OK1 OVT P2P P2W PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO RAO RHI ROL RPM SUPJJ SV3 TOX TR2 UDS UKHRP W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAYXX CITATION 24P CGR CUY CVF ECM EIF NPM RHF ROX 7X8 5PM |
| ID | FETCH-LOGICAL-c5040-cd071adcc02a376d6eae191adca6e5cc59315ad63f4e935b3075c08efb0855243 |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Thu Aug 21 18:33:31 EDT 2025 Fri Jul 11 06:02:50 EDT 2025 Wed Feb 19 02:31:04 EST 2025 Tue Jul 01 01:17:16 EDT 2025 Thu Apr 24 22:52:59 EDT 2025 Wed Aug 20 07:26:27 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | S1 |
| Keywords | Clinical trials Immune checkpoint inhibitors PD‐1/PD‐L1 Combination therapy Non‐small‐cell lung cancer |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model AlphaMed Press 2019. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5040-cd071adcc02a376d6eae191adca6e5cc59315ad63f4e935b3075c08efb0855243 |
| Notes | . Disclosures of potential conflicts of interest may be found at the end of this article Contributed equally ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Disclosures of potential conflicts of interest may be found at the end of this article. |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6394772 |
| PMID | 30819829 |
| PQID | 2187513854 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6394772 proquest_miscellaneous_2187513854 pubmed_primary_30819829 crossref_primary_10_1634_theoncologist_2019_IO_S1_s05 crossref_citationtrail_10_1634_theoncologist_2019_IO_S1_s05 wiley_primary_10_1634_theoncologist_2019_IO_S1_s05_ONCO12760 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2019 2019-02-01 2019-02-00 20190201 |
| PublicationDateYYYYMMDD | 2019-02-01 |
| PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2019 |
| Publisher | John Wiley & Sons, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc |
| References | 2010; 11 2017; 7 2015; 37 2017; 8 2017; 2 2017; 3 2012; 366 2015; 75 2015; 33 1996; 183 2016; 387 2016; 100 2015; 107 2015; 348 2011; 17 2017; 551 2017; 276 1992; 11 2017; 355 2013; 5 2017; 114 2017; 9 2017; 359 2012; 209 2014; 64 2010; 65 2015; 136 2017; 77 2017; 35 2015; 373 2018; 378 2008; 26 2016; 352 2011; 68 2009; 361 2018; 78 2014; 9 2011; 480 2017; 169 2011; 29 2016; 351 2018; 36 2007; 19 2006; 439 2015; 6 2015; 5 2010; 207 2017; 28 2017; 22 1987; 328 1993; 85 2002; 8 2010; 363 2013; 342 2017; 170 2017; 376 2016; 17 2017; 377 1999; 5 2015; 7 2016; 14 1994; 86 2000; 192 2018; 24 2016; 11 1994; 9 2018; 19 2016; 5 2016; 1 2018; 359 2017; 15 1992; 176 2017; 17 2017; 16 2017; 11 2017; 10 2017; 12 2016; 21 1996; 271 2016; 375 2017; 19 2017; 18 1910; 3 2018; 10 2017; 389 1995; 182 2017; 545 2017; 106 2016; 66 2016; 22 Liu (2021122508155345900_R6) 2017; 10 Garassino (2021122508155345900_R73) 2018; 19 Okazaki (2021122508155345900_R38) 2007; 19 Overman (2021122508155345900_R90) 2017; 18 Barry (2021122508155345900_R46) 2018; 24 Forde (2021122508155345900_R74) 2018; 378 Wei (2021122508155345900_R68) 2017; 170 Antonia (2021122508155345900_R70) 2016; 17 Bhatnagar (2021122508155345900_R8) 2017; 22 Scognamiglio (2021122508155345900_R82) 2016; 17 Dillman (2021122508155345900_R19) 1994; 9 Langer (2021122508155345900_R62) 2016; 17 Liu (2021122508155345900_R102) 2017; 11 Yeh (2021122508155345900_R77) 2018; 10 Rittmeyer (2021122508155345900_R55) 2017; 389 Krummel (2021122508155345900_R25) 1996; 183 Frankel (2021122508155345900_R94) 2017; 19 Larkins (2021122508155345900_R10) 2017; 22 Gopalakrishnan (2021122508155345900_R92) 2017; 359 Brahmer (2021122508155345900_R51) 2015; 373 Siegel (2021122508155345900_R49) 2014; 64 Rosell (2021122508155345900_R109) 2009; 361 Wu (2021122508155345900_R78) 2018; 78 D'Angelo (2021122508155345900_R110) 2011; 29 Borghaei (2021122508155345900_R52) 2015; 373 Xu (2021122508155345900_R14) 2017; 22 Sato-Kaneko (2021122508155345900_R107) 2017; 2 Roszik (2021122508155345900_R88) 2016; 14 Teng (2021122508155345900_R104) 2015; 75 Antonia (2021122508155345900_R76) 2017; 377 Shin (2021122508155345900_R3) 2015; 33 Geng (2021122508155345900_R122) 2015; 37 Hodi (2021122508155345900_R28) 2010; 363 Andrews (2021122508155345900_R101) 2017; 276 Lopes (2021122508155345900_R59) 2018; 36 He (2021122508155345900_R100) 2017; 12 Gupta (2021122508155345900_R114) 2017; 8 Pai-Scherf (2021122508155345900_R16) 2017; 22 Krieg (2021122508155345900_R105) 2018; 24 Mellman (2021122508155345900_R1) 2011; 480 Teraoka (2021122508155345900_R118) 2017; 12 Thommen (2021122508155345900_R106) 2018; 24 Brahmer (2021122508155345900_R32) 2012; 366 Aguiar (2021122508155345900_R81) 2017; 9 Ramos-Esquivel (2021122508155345900_R57) 2017; 2 Ning (2021122508155345900_R12) 2017; 22 Aguiar (2021122508155345900_R91) 2015; 7 Balachandran (2021122508155345900_R95) 2017; 551 Kim (2021122508155345900_R13) 2017; 77 Rizvi (2021122508155345900_R85) 2015; 348 Kasamon (2021122508155345900_R11) 2017; 22 Dong (2021122508155345900_R39) 2002; 8 Ahn (2021122508155345900_R75) 2015; 33 Brunet (2021122508155345900_R4) 1987; 328 Dong (2021122508155345900_R31) 1999; 5 Linsley (2021122508155345900_R26) 1992; 176 Wei (2021122508155345900_R42) 2015; 5 Ven (2021122508155345900_R43) 2017; 3 Kline (2021122508155345900_R7) 2010; 11 Couzin-Frankel (2021122508155345900_R23) 2013; 342 Fehrenbacher (2021122508155345900_R56) 2016; 387 Bagley (2021122508155345900_R120) 2017; 106 Liu (2021122508155345900_R79) 2017; 10 Sanmamed (2021122508155345900_R117) 2017; 28 Hofman (2021122508155345900_R84) 2017; 17 Huang (2021122508155345900_R119) 2017; 545 Einstein (2021122508155345900_R98) 2017; 15 Nishio (2021122508155345900_R112) 2016; 1 (2021122508155345900_R97) 2017; 7 Freeman (2021122508155345900_R37) 2000; 192 Overacre-Delgoffe (2021122508155345900_R44) 2017; 169 Traynor (2021122508155345900_R29) 2011; 68 Socinski (2021122508155345900_R67) 2018; 378 Sul (2021122508155345900_R17) 2016; 21 Peters (2021122508155345900_R61) 2017; 35 Cheever (2021122508155345900_R22) 2011; 17 Cabel (2021122508155345900_R116) 2017; 28 Khanna (2021122508155345900_R50) 2017; 18 Chen (2021122508155345900_R48) 2016; 66 Paz-Ares (2021122508155345900_R65) 2018; 36 Barber (2021122508155345900_R5) 2006; 439 Blank (2021122508155345900_R96) 2016; 352 Mok (2021122508155345900_R71) 2016; 11 Pinato (2021122508155345900_R83) 2016; 5 Horn (2021122508155345900_R53) 2017; 35 Sakuishi (2021122508155345900_R103) 2010; 207 Spranger (2021122508155345900_R40) 2013; 5 Kamphorst (2021122508155345900_R35) 2017; 355 Shi (2021122508155345900_R111) 2014; 9 Ishida (2021122508155345900_R30) 1992; 11 Hellmann (2021122508155345900_R69) 2018; 378 Krummel (2021122508155345900_R24) 1995; 182 Kazandjian (2021122508155345900_R9) 2016; 21 Leach (2021122508155345900_R27) 1996; 271 Kamphorst (2021122508155345900_R121) 2017; 114 Hellmann (2021122508155345900_R99) 2017; 18 Reck (2021122508155345900_R63) 2018; 10 Rosenberg (2021122508155345900_R21) 1994; 86 Sclafani (2021122508155345900_R15) 2017; 18 Carbone (2021122508155345900_R60) 2017; 376 Herbst (2021122508155345900_R54) 2016; 387 Jotte (2021122508155345900_R66) 2018; 36 Ferlay (2021122508155345900_R47) 2015; 136 Gandini (2021122508155345900_R80) 2016; 100 Routy (2021122508155345900_R93) 2018; 359 Coley (2021122508155345900_R18) 1910; 3 Wulan (2021122508155345900_R115) 2010; 65 Goodman (2021122508155345900_R87) 2017; 16 McGranahan (2021122508155345900_R86) 2016; 351 Reck (2021122508155345900_R58) 2016; 375 Yokosuka (2021122508155345900_R36) 2012; 209 Keir (2021122508155345900_R33) 2008; 26 Lee (2021122508155345900_R41) 2015; 6 Luksza (2021122508155345900_R89) 2017; 551 Gainor (2021122508155345900_R113) 2016; 22 Brower (2021122508155345900_R2) 2015; 107 Hui (2021122508155345900_R34) 2017; 355 Gordon (2021122508155345900_R45) 2017; 545 Triplett (2021122508155345900_R108) 2018; 36 Gandhi (2021122508155345900_R64) 2018; 378 Planchard (2021122508155345900_R72) 2016; 17 Rosenberg (2021122508155345900_R20) 1993; 85 |
| References_xml | – volume: 363 start-page: 711 year: 2010 end-page: 723 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med – volume: 3 start-page: 0110 year: 2017 end-page: 2016 article-title: High PD‐1 expression on regulatory and effector T‐cells in lung cancer draining lymph nodes publication-title: ERJ Open Res – volume: 12 start-page: 814 year: 2017 end-page: 823 article-title: LAG‐3 protein expression in non‐small cell lung cancer and its relationship with PD‐1/PD‐L1 and tumor‐infiltrating lymphocytes publication-title: J Thorac Oncol – volume: 17 start-page: 3520 year: 2011 end-page: 3526 article-title: PROVENGE (sipuleucel‐T) in prostate cancer: The first FDA‐approved therapeutic cancer vaccine publication-title: Clin Cancer Res – volume: 19 start-page: 813 year: 2007 end-page: 824 article-title: PD‐1 and pD‐1 ligands: From discovery to clinical application publication-title: Int Immunol – volume: 378 start-page: 2093 year: 2018 end-page: 2104 article-title: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden publication-title: N Engl J Med – volume: 11 start-page: 235 year: 2017 end-page: 247 article-title: T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer publication-title: Mol Oncol – volume: 9 start-page: 499 year: 2017 end-page: 506 article-title: PD‐L1 expression as a predictive biomarker in advanced non‐small‐cell lung cancer: Updated survival data publication-title: Immunotherapy – volume: 77 start-page: 929 year: 2017 end-page: 937 article-title: Avelumab: First global approval publication-title: Drugs – volume: 11 start-page: 1354 year: 2010 end-page: 1359 article-title: Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer publication-title: Curr Opin Investig Drugs – volume: 18 start-page: 31 year: 2017 end-page: 41 article-title: Nivolumab plus ipilimumab as first‐line treatment for advanced non‐small‐cell lung cancer (CheckMate 012): Results of an open‐label, phase 1, multicohort study publication-title: Lancet Oncol – volume: 26 start-page: 677 year: 2008 end-page: 704 article-title: PD‐1 and its ligands in tolerance and immunity publication-title: Annu Rev Immunol – volume: 36 start-page: LBA4 issue: suppl 18 year: 2018 article-title: Pembrolizumab (pembro) versus platinum‐based chemotherapy (chemo) as first‐line therapy for advanced/metastatic NSCLC with a PD‐L1 tumor proportion score (TPS) ≥1%: Open‐label, phase 3 KEYNOTE‐042 study publication-title: J Clin Oncol – volume: 17 start-page: 232 year: 2016 end-page: 236.e231 article-title: A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: Rationale and protocol design of the ARCTIC study publication-title: Clin Lung Cancer – volume: 11 start-page: S140 year: 2016 end-page: S141 article-title: 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SOC) platinum‐based chemotherapy in the first‐line treatment of patients (pts) with advanced or metastatic NSCLC publication-title: J Thorac Oncol – volume: 5 start-page: 2190 year: 2015 end-page: 2201 article-title: Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non‐small‐cell lung cancer patients publication-title: Am J Cancer Res – volume: 276 start-page: 80 year: 2017 end-page: 96 article-title: LAG3 (CD223) as a cancer immunotherapy target publication-title: Immunol Rev – volume: 5 start-page: e1213934 year: 2016 article-title: Intra‐tumoral heterogeneity in the expression of programmed‐death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy publication-title: Oncoimmunology – volume: 182 start-page: 459 year: 1995 end-page: 465 article-title: CD28 and CTLA‐4 have opposing effects on the response of T cells to stimulation publication-title: J Exp Med – volume: 24 start-page: 144 year: 2018 end-page: 153 article-title: High‐dimensional single‐cell analysis predicts response to anti‐PD‐1 immunotherapy publication-title: Nat Med – volume: 68 start-page: 768 year: 2011 article-title: Ipilimumab approved for metastatic melanoma publication-title: Am J Health System Pharm – volume: 28 start-page: 1988 year: 2017 end-page: 1995 article-title: Changes in serum interleukin‐8 (IL‐8) levels reflect and predict response to anti‐PD‐1 treatment in melanoma and non‐small‐cell lung cancer patients publication-title: Ann Oncol – volume: 3 start-page: 1 year: 1910 end-page: 48 article-title: The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus) publication-title: Proc R Soc Med – volume: 209 start-page: 1201 year: 2012 end-page: 1217 article-title: Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 publication-title: J Exp Med – volume: 29 start-page: 2066 year: 2011 end-page: 2070 article-title: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas publication-title: J Clin Oncol – volume: 22 start-page: 311 year: 2017 end-page: 317 article-title: FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti‐angiogenic therapy and exploratory predictive biomarker analysis publication-title: The Oncologist – volume: 351 start-page: 1463 year: 2016 end-page: 1469 article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade publication-title: Science – volume: 328 start-page: 267 year: 1987 end-page: 270 article-title: A new member of the immunoglobulin superfamily‐‐CTLA‐4 publication-title: Nature – volume: 6 start-page: 7 year: 2015 end-page: 17 article-title: Reinvigorating exhausted T cells by blockade of the PD‐1 pathway publication-title: For Immunopathol Dis Therap – volume: 377 start-page: 1919 year: 2017 end-page: 1929 article-title: Durvalumab after chemoradiotherapy in stage III non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 18 start-page: 1182 year: 2017 end-page: 1191 article-title: Nivolumab in patients with metastatic DNA mismatch repair‐deficient or microsatellite instability‐high colorectal cancer (CheckMate 142): An open‐label, multicentre, phase 2 study publication-title: Lancet Oncol – volume: 8 start-page: 793 year: 2002 end-page: 800 article-title: Tumor‐associated B7‐H1 promotes t‐cell apoptosis: A potential mechanism of immune evasion publication-title: Nat Med – volume: 136 start-page: E359 year: 2015 end-page: 386 article-title: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer – volume: 24 start-page: 994 year: 2018 end-page: 1004 article-title: A transcriptionally and functionally distinct PD‐1+ CD8+ T cell pool with predictive potential in non‐small‐cell lung cancer treated with PD‐1 blockade publication-title: Nat Med – volume: 375 start-page: 1823 year: 2016 end-page: 1833 article-title: Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 36 start-page: LBA9000 issue: suppl 18 year: 2018 article-title: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab‐paclitaxel vs carboplatin + nab‐paclitaxel as 1L therapy in advanced squamous NSCLC publication-title: J Clin Oncol – volume: 21 start-page: 634 year: 2016 end-page: 642 article-title: FDA approval summary: Nivolumab for the treatment of metastatic non‐small cell lung cancer with progression on or after platinum‐based chemotherapy publication-title: The Oncologist – volume: 11 start-page: 3887 year: 1992 end-page: 3895 article-title: Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J – volume: 114 start-page: 4993 year: 2017 end-page: 4998 article-title: Proliferation of PD‐1+ CD8 T cells in peripheral blood after PD‐1‐targeted therapy in lung cancer patients publication-title: Proc Natl Acad Sci USA – volume: 5 start-page: 1365 year: 1999 end-page: 1369 article-title: B7‐H1, a third member of the B7 family, co‐stimulates T‐cell proliferation and interleukin‐10 secretion publication-title: Nat Med – volume: 66 start-page: 115 year: 2016 end-page: 132 article-title: Cancer statistics in China, 2015 publication-title: CA Cancer J Clin – volume: 75 start-page: 2139 year: 2015 end-page: 2145 article-title: Classifying cancers based on T‐cell infiltration and PD‐L1 publication-title: Cancer Res – volume: 17 start-page: 299 year: 2016 end-page: 308 article-title: Safety and antitumour activity of durvalumab plus tremelimumab in non‐small cell lung cancer: A multicentre, phase 1b study publication-title: Lancet Oncol – volume: 348 start-page: 124 year: 2015 end-page: 128 article-title: Cancer immunology. Mutational landscape determines sensitivity to PD‐1 blockade in non‐small cell lung cancer publication-title: Science – volume: 359 start-page: 91 year: 2018 end-page: 97 article-title: Gut microbiome influences efficacy of PD‐1‐based immunotherapy against epithelial tumors publication-title: Science – volume: 7 start-page: 1133 year: 2015 end-page: 1134 article-title: MMR deficiency may lead to a high immunogenicity and then an improvement in anti‐PD‐1 efficacy for metastatic colorectal cancer publication-title: Immunotherapy – volume: 355 start-page: 1428 year: 2017 end-page: 1433 article-title: T cell costimulatory receptor CD28 is a primary target for PD‐1‐mediated inhibition publication-title: Science – volume: 378 start-page: 2288 year: 2018 end-page: 2301 article-title: Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med – volume: 359 start-page: 97 year: 2017 end-page: 103 article-title: Gut microbiome modulates response to anti‐PD‐1 immunotherapy in melanoma patients publication-title: Science – volume: 352 start-page: 658 year: 2016 end-page: 660 article-title: Cancer immunology. The “cancer immunogram.” publication-title: Science – volume: 18 start-page: 13 year: 2017 end-page: 22 article-title: Immunotherapy comes of age in lung cancer publication-title: Clin Lung Cancer – volume: 17 start-page: 1097 year: 2017 end-page: 1108 article-title: PD‐L1 immunohistochemistry for non‐small cell lung carcinoma: Which strategy should be adopted? publication-title: Expert Rev Mol Diagn – volume: 85 start-page: 622 year: 1993 end-page: 632 article-title: Prospective randomized trial of high‐dose interleukin‐2 alone or in conjunction with lymphokine‐activated killer cells for the treatment of patients with advanced cancer publication-title: J Natl Cancer Inst – volume: 17 start-page: E790 year: 2016 article-title: Variability in immunohistochemical detection of programmed death ligand 1 (PD‐L1) in cancer tissue types publication-title: Int J Mol Sci – volume: 7 start-page: OF2 year: 2017 publication-title: Cancer Discov – volume: 37 start-page: 1560 year: 2015 end-page: 1571 article-title: Prognostic role of tumor‐infiltrating lymphocytes in lung cancer: A meta‐analysis publication-title: Cell Physiol Biochem – volume: 8 start-page: 1162 year: 2017 article-title: Geography, ethnicity or subsistence‐specific variations in human microbiome composition and diversity publication-title: Front Microbiol – volume: 22 start-page: 743 year: 2017 end-page: 749 article-title: FDA approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum‐containing chemotherapy publication-title: The Oncologist – volume: 22 start-page: 1392 year: 2017 end-page: 1399 article-title: FDA approval summary: Pembrolizumab for treatment of metastatic non‐small cell lung cancer: First‐line therapy and beyond publication-title: The Oncologist – volume: 19 start-page: 521 year: 2018 end-page: 536 article-title: Durvalumab as third‐line or later treatment for advanced non‐small‐cell lung cancer (ATLANTIC): An open‐label, single‐arm, phase 2 study publication-title: Lancet Oncol – volume: 545 start-page: 495 year: 2017 end-page: 499 article-title: PD‐1 expression by tumour‐associated macrophages inhibits phagocytosis and tumour immunity publication-title: Nature – volume: 389 start-page: 255 year: 2017 end-page: 265 article-title: Atezolizumab versus docetaxel in patients with previously treated non‐small‐cell lung cancer (OAK): A phase 3, open‐label, multicentre randomised controlled trial publication-title: Lancet – volume: 10 start-page: 93 year: 2018 end-page: 105 article-title: Pembrolizumab as first‐line therapy for metastatic non‐small‐cell lung cancer publication-title: Immunotherapy – volume: 10 start-page: S451 year: 2018 end-page: S459 article-title: Neoadjuvant and consolidation immuno‐oncology therapy in stage III non‐small cell lung cancer publication-title: J Thorac Dis – volume: 376 start-page: 2415 year: 2017 end-page: 2426 article-title: First‐line nivolumab in stage IV or recurrent non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 36 start-page: 758 year: 2018 end-page: 764 article-title: Reversal of indoleamine 2,3‐dioxygenase‐mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme publication-title: Nat Biotechnol – volume: 35 start-page: 2781 year: 2017 end-page: 2789 article-title: Phase II trial of atezolizumab as first‐line or subsequent therapy for patients with programmed death‐ligand 1‐selected advanced non‐small‐cell lung cancer (BIRCH) publication-title: J Clin Oncol – volume: 36 start-page: 105A issue: suppl 15 year: 2018 article-title: Phase 3 study of carboplatin‐paclitaxel/nab‐paclitaxel (chemo) with or without pembrolizumab (pembro) for patients (pts) with metastatic squamous (sq) non‐small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 22 start-page: 4585 year: 2016 end-page: 4593 article-title: EGFR mutations and ALK rearrangements are associated with low response rates to PD‐1 pathway blockade in non‐small cell lung cancer: A retrospective analysis publication-title: Clin Cancer Res – volume: 169 start-page: 1130 year: 2017 end-page: 1141.e1111 article-title: Interferon‐γ drives Treg fragility to promote anti‐tumor immunity publication-title: Cell – volume: 192 start-page: 1027 year: 2000 end-page: 1034 article-title: Engagement of the PD‐1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J Exp Med – volume: 12 start-page: 1798 year: 2017 end-page: 1805 article-title: Early immune‐related adverse events and association with outcome in advfanced non‐small cell lung cancer patients treated with nivolumab: A prospective cohort study publication-title: J Thorac Oncol – volume: 545 start-page: 60 year: 2017 end-page: 65 article-title: T‐cell invigoration to tumour burden ratio associated with anti‐PD‐1 response publication-title: Nature – volume: 480 start-page: 480 year: 2011 end-page: 489 article-title: Cancer immunotherapy comes of age publication-title: Nature – volume: 355 start-page: 1423 year: 2017 end-page: 1427 article-title: Rescue of exhausted CD8 t cells by PD‐1‐targeted therapies is CD28‐dependent publication-title: Science – volume: 78 start-page: CT114A issue: suppl 13 year: 2018 article-title: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non‐small cell lung cancer (NSCLC): Results of the phase 3 CheckMate 078 study publication-title: Cancer Res – volume: 16 start-page: 2598 year: 2017 end-page: 2608 article-title: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers publication-title: Mol Cancer Ther – volume: 5 start-page: 200ra116 year: 2013 article-title: Up‐regulation of PD‐L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells publication-title: Sci Transl Med – volume: 22 start-page: 873 year: 2017 end-page: 878 article-title: FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum‐containing chemotherapy publication-title: The Oncologist – volume: 14 start-page: 168 year: 2016 article-title: Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set publication-title: BMC Med – volume: 35 start-page: 3924 year: 2017 end-page: 3933 article-title: Nivolumab versus docetaxel in previously treated patients with advanced non‐small‐cell lung cancer: Two‐year outcomes from two randomized, open‐label, phase III trials (CheckMate 017 and CheckMate 057) publication-title: J Clin Oncol – volume: 22 start-page: 1347 year: 2017 end-page: 1353 article-title: FDA approval summary: Daratumumab for treatment of multiple myeloma after one prior therapy publication-title: The Oncologist – volume: 183 start-page: 2533 year: 1996 end-page: 2540 article-title: CTLA‐4 engagement inhibits IL‐2 accumulation and cell cycle progression upon activation of resting T cells publication-title: J Exp Med – volume: 15 start-page: 478 year: 2017 end-page: 488 article-title: Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer publication-title: Clin Adv Hematol Oncol – volume: 361 start-page: 958 year: 2009 end-page: 967 article-title: Screening for epidermal growth factor receptor mutations in lung cancer publication-title: N Engl J Med – volume: 207 start-page: 2187 year: 2010 end-page: 2194 article-title: Targeting TIM‐3 and PD‐1 pathways to reverse T cell exhaustion and restore anti‐tumor immunity publication-title: J Exp Med – volume: 64 start-page: 9 year: 2014 end-page: 29 article-title: Cancer statistics, 2014 publication-title: CA Cancer J Clin – volume: 373 start-page: 1627 year: 2015 end-page: 1639 article-title: Nivolumab versus docetaxel in advanced nonsquamous non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 65 start-page: 315 year: 2010 end-page: 319 article-title: Ethnic differences in body composition and the associated metabolic profile: A comparative study between Asians and Caucasians publication-title: Maturitas – volume: 24 start-page: 1178 year: 2018 end-page: 1191 article-title: A natural killer‐dendritic cell axis defines checkpoint therapy‐responsive tumor microenvironments publication-title: Nat Med – volume: 18 start-page: 1141 year: 2017 end-page: 1142 article-title: PD‐1 inhibition in metastatic dMMR/MSI‐H colorectal cancer publication-title: Lancet Oncol – volume: 373 start-page: 123 year: 2015 end-page: 135 article-title: Nivolumab versus docetaxel in advanced squamous‐cell non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 9 start-page: 183 year: 1994 end-page: 209 article-title: The clinical experience with interleukin‐2 in cancer therapy publication-title: Cancer Biother – volume: 551 start-page: 517 year: 2017 end-page: 520 article-title: A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy publication-title: Nature – volume: 100 start-page: 88 year: 2016 end-page: 98 article-title: PD‐L1 expression in cancer patients receiving anti PD‐1/PD‐L1 antibodies: A systematic review and meta‐analysis publication-title: Crit Rev Oncol Hematol – volume: 378 start-page: 1976 year: 2018 end-page: 1986 article-title: Neoadjuvant PD‐1 blockade in resectable lung cancer publication-title: N Engl J Med – volume: 17 start-page: 1497 year: 2016 end-page: 1508 article-title: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non‐squamous non‐small‐cell lung cancer: A randomised, phase 2 cohort of the open‐label KEYNOTE‐021 study publication-title: Lancet Oncol – volume: 10 start-page: 174 year: 2017 article-title: Recent development in clinical applications of PD‐1 and PD‐L1 antibodies for cancer immunotherapy publication-title: J Hematol Oncol – volume: 551 start-page: 512 year: 2017 end-page: 516 article-title: Identification of unique neoantigen qualities in long‐term survivors of pancreatic cancer publication-title: Nature – volume: 342 start-page: 1432 year: 2013 end-page: 1433 article-title: Breakthrough of the year 2013 publication-title: Cancer immunotherapy. Science – volume: 28 start-page: 1996 year: 2017 end-page: 2001 article-title: Circulating tumor DNA changes for early monitoring of anti‐PD1 immunotherapy: A proof‐of‐concept study publication-title: Ann Oncol – volume: 86 start-page: 1159 year: 1994 end-page: 1166 article-title: Treatment of patients with metastatic melanoma with autologous tumor‐infiltrating lymphocytes and interleukin 2 publication-title: J Natl Cancer Inst – volume: 19 start-page: 848 year: 2017 end-page: 855 article-title: Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients publication-title: Neoplasia – volume: 107 start-page: djv069 year: 2015 article-title: Checkpoint blockade immunotherapy for cancer comes of age publication-title: J Natl Cancer Inst – volume: 9 start-page: 154 year: 2014 end-page: 162 article-title: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non‐small‐cell lung cancer of adenocarcinoma histology (PIONEER) publication-title: J Thorac Oncol – volume: 170 start-page: 1120 year: 2017 end-page: 1133.e1117 article-title: Distinct cellular mechanisms underlie anti‐CTLA‐4 and anti‐PD‐1 checkpoint blockade publication-title: Cell – volume: 10 start-page: 136 year: 2017 article-title: Ongoing clinical trials of PD‐1 and PD‐L1 inhibitors for lung cancer in China publication-title: J Hematol Oncol – volume: 33 start-page: 2660 year: 2015 end-page: 2666 article-title: Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non‐small‐cell lung cancer: KCSG‐LU05‐04 publication-title: J Clin Oncol – volume: 271 start-page: 1734 year: 1996 end-page: 1736 article-title: Enhancement of antitumor immunity by CTLA‐4 blockade publication-title: Science – volume: 33 start-page: 23 year: 2015 end-page: 35 article-title: The evolution of checkpoint blockade as a cancer therapy: What's here, what's next? publication-title: Curr Opin Immunol – volume: 439 start-page: 682 year: 2006 end-page: 687 article-title: Restoring function in exhausted CD8 T cells during chronic viral infection publication-title: Nature – volume: 366 start-page: 2455 year: 2012 end-page: 2465 article-title: Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer publication-title: N Engl J Med – volume: 387 start-page: 1540 year: 2016 end-page: 1550 article-title: Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): A randomised controlled trial publication-title: Lancet – volume: 106 start-page: 1 year: 2017 end-page: 7 article-title: Pretreatment neutrophil‐to‐lymphocyte ratio as a marker of outcomes in nivolumab‐treated patients with advanced non‐small‐cell lung cancer publication-title: Lung Cancer – volume: 2 start-page: e000236 year: 2017 article-title: Anti‐PD‐1/anti‐PD‐L1 immunotherapy versus docetaxel for previously treated advanced non‐small cell lung cancer: A systematic review and meta‐analysis of randomised clinical trials publication-title: ESMO Open – volume: 387 start-page: 1837 year: 2016 end-page: 1846 article-title: Atezolizumab versus docetaxel for patients with previously treated non‐small‐cell lung cancer (POPLAR): A multicentre, open‐label, phase 2 randomised controlled trial publication-title: Lancet – volume: 176 start-page: 1595 year: 1992 end-page: 1604 article-title: Coexpression and functional cooperation of CTLA‐4 and CD28 on activated T lymphocytes publication-title: J Exp Med – volume: 2 start-page: 93397 year: 2017 article-title: Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer publication-title: JCI Insight – volume: 22 start-page: 585 year: 2017 end-page: 591 article-title: FDA approval summary: Nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma publication-title: The Oncologist – volume: 1 start-page: e000108 year: 2016 article-title: Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non‐squamous non‐small cell lung cancer publication-title: ESMO Open – volume: 21 start-page: 643 year: 2016 end-page: 650 article-title: FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non‐small cell lung cancer whose tumors express programmed death‐ligand 1 publication-title: The Oncologist – volume: 378 start-page: 2078 year: 2018 end-page: 2092 article-title: Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 136 start-page: E359 year: 2015 ident: 2021122508155345900_R47 article-title: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer doi: 10.1002/ijc.29210 – volume: 12 start-page: 1798 year: 2017 ident: 2021122508155345900_R118 article-title: Early immune-related adverse events and association with outcome in advfanced non-small cell lung cancer patients treated with nivolumab: A prospective cohort study publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.08.022 – volume: 19 start-page: 521 year: 2018 ident: 2021122508155345900_R73 article-title: Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30144-X – volume: 10 start-page: 174 year: 2017 ident: 2021122508155345900_R6 article-title: Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0541-9 – volume: 22 start-page: 1347 year: 2017 ident: 2021122508155345900_R8 article-title: FDA approval summary: Daratumumab for treatment of multiple myeloma after one prior therapy publication-title: The Oncologist doi: 10.1634/theoncologist.2017-0229 – volume: 12 start-page: 814 year: 2017 ident: 2021122508155345900_R100 article-title: LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.01.019 – volume: 5 start-page: 1365 year: 1999 ident: 2021122508155345900_R31 article-title: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion publication-title: Nat Med doi: 10.1038/70932 – volume: 271 start-page: 1734 year: 1996 ident: 2021122508155345900_R27 article-title: Enhancement of antitumor immunity by CTLA-4 blockade publication-title: Science doi: 10.1126/science.271.5256.1734 – volume: 100 start-page: 88 year: 2016 ident: 2021122508155345900_R80 article-title: PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2016.02.001 – volume: 24 start-page: 144 year: 2018 ident: 2021122508155345900_R105 article-title: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy publication-title: Nat Med doi: 10.1038/nm.4466 – volume: 68 start-page: 768 year: 2011 ident: 2021122508155345900_R29 article-title: Ipilimumab approved for metastatic melanoma publication-title: Am J Health System Pharm – volume: 545 start-page: 495 year: 2017 ident: 2021122508155345900_R45 article-title: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity publication-title: Nature doi: 10.1038/nature22396 – volume: 3 start-page: 0110 year: 2017 ident: 2021122508155345900_R43 article-title: High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes publication-title: ERJ Open Res – volume: 375 start-page: 1823 year: 2016 ident: 2021122508155345900_R58 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 – volume: 24 start-page: 994 year: 2018 ident: 2021122508155345900_R106 article-title: A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade publication-title: Nat Med doi: 10.1038/s41591-018-0057-z – volume: 545 start-page: 60 year: 2017 ident: 2021122508155345900_R119 article-title: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response publication-title: Nature doi: 10.1038/nature22079 – volume: 10 start-page: S451 year: 2018 ident: 2021122508155345900_R77 article-title: Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer publication-title: J Thorac Dis doi: 10.21037/jtd.2018.01.109 – volume: 33 start-page: 23 year: 2015 ident: 2021122508155345900_R3 article-title: The evolution of checkpoint blockade as a cancer therapy: What's here, what's next? publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2015.01.006 – volume: 439 start-page: 682 year: 2006 ident: 2021122508155345900_R5 article-title: Restoring function in exhausted CD8 T cells during chronic viral infection publication-title: Nature doi: 10.1038/nature04444 – volume: 28 start-page: 1996 year: 2017 ident: 2021122508155345900_R116 article-title: Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study publication-title: Ann Oncol doi: 10.1093/annonc/mdx212 – volume: 366 start-page: 2455 year: 2012 ident: 2021122508155345900_R32 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 – volume: 17 start-page: E790 year: 2016 ident: 2021122508155345900_R82 article-title: Variability in immunohistochemical detection of programmed death ligand 1 (PD-L1) in cancer tissue types publication-title: Int J Mol Sci doi: 10.3390/ijms17050790 – volume: 207 start-page: 2187 year: 2010 ident: 2021122508155345900_R103 article-title: Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity publication-title: J Exp Med doi: 10.1084/jem.20100643 – volume: 11 start-page: 235 year: 2017 ident: 2021122508155345900_R102 article-title: T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer publication-title: Mol Oncol doi: 10.1002/1878-0261.12029 – volume: 28 start-page: 1988 year: 2017 ident: 2021122508155345900_R117 article-title: Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients publication-title: Ann Oncol doi: 10.1093/annonc/mdx190 – volume: 355 start-page: 1428 year: 2017 ident: 2021122508155345900_R34 article-title: T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition publication-title: Science doi: 10.1126/science.aaf1292 – volume: 2 start-page: e000236 year: 2017 ident: 2021122508155345900_R57 article-title: Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: A systematic review and meta-analysis of randomised clinical trials publication-title: ESMO Open doi: 10.1136/esmoopen-2017-000236 – volume: 22 start-page: 4585 year: 2016 ident: 2021122508155345900_R113 article-title: EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-3101 – volume: 10 start-page: 136 year: 2017 ident: 2021122508155345900_R79 article-title: Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0506-z – volume: 352 start-page: 658 year: 2016 ident: 2021122508155345900_R96 article-title: Cancer immunology. The “cancer immunogram.” publication-title: Science doi: 10.1126/science.aaf2834 – volume: 1 start-page: e000108 year: 2016 ident: 2021122508155345900_R112 article-title: Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer publication-title: ESMO Open – volume: 11 start-page: 1354 year: 2010 ident: 2021122508155345900_R7 article-title: Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer publication-title: Curr Opin Investig Drugs – volume: 176 start-page: 1595 year: 1992 ident: 2021122508155345900_R26 article-title: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes publication-title: J Exp Med doi: 10.1084/jem.176.6.1595 – volume: 378 start-page: 2288 year: 2018 ident: 2021122508155345900_R67 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1716948 – volume: 14 start-page: 168 year: 2016 ident: 2021122508155345900_R88 article-title: Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set publication-title: BMC Med doi: 10.1186/s12916-016-0705-4 – volume: 75 start-page: 2139 year: 2015 ident: 2021122508155345900_R104 article-title: Classifying cancers based on T-cell infiltration and PD-L1 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-0255 – volume: 8 start-page: 793 year: 2002 ident: 2021122508155345900_R39 article-title: Tumor-associated B7-H1 promotes t-cell apoptosis: A potential mechanism of immune evasion publication-title: Nat Med doi: 10.1038/nm730 – volume: 373 start-page: 123 year: 2015 ident: 2021122508155345900_R51 article-title: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 – volume: 355 start-page: 1423 year: 2017 ident: 2021122508155345900_R35 article-title: Rescue of exhausted CD8 t cells by PD-1-targeted therapies is CD28-dependent publication-title: Science doi: 10.1126/science.aaf0683 – volume: 15 start-page: 478 year: 2017 ident: 2021122508155345900_R98 article-title: Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer publication-title: Clin Adv Hematol Oncol – volume: 78 start-page: CT114A issue: suppl 13 year: 2018 ident: 2021122508155345900_R78 article-title: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): Results of the phase 3 CheckMate 078 study publication-title: Cancer Res doi: 10.1158/1538-7445.AM2018-CT114 – volume: 182 start-page: 459 year: 1995 ident: 2021122508155345900_R24 article-title: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation publication-title: J Exp Med doi: 10.1084/jem.182.2.459 – volume: 64 start-page: 9 year: 2014 ident: 2021122508155345900_R49 article-title: Cancer statistics, 2014 publication-title: CA Cancer J Clin doi: 10.3322/caac.21208 – volume: 387 start-page: 1540 year: 2016 ident: 2021122508155345900_R54 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 37 start-page: 1560 year: 2015 ident: 2021122508155345900_R122 article-title: Prognostic role of tumor-infiltrating lymphocytes in lung cancer: A meta-analysis publication-title: Cell Physiol Biochem doi: 10.1159/000438523 – volume: 19 start-page: 848 year: 2017 ident: 2021122508155345900_R94 article-title: Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients publication-title: Neoplasia doi: 10.1016/j.neo.2017.08.004 – volume: 183 start-page: 2533 year: 1996 ident: 2021122508155345900_R25 article-title: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells publication-title: J Exp Med doi: 10.1084/jem.183.6.2533 – volume: 5 start-page: 200ra116 year: 2013 ident: 2021122508155345900_R40 article-title: Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3006504 – volume: 6 start-page: 7 year: 2015 ident: 2021122508155345900_R41 article-title: Reinvigorating exhausted T cells by blockade of the PD-1 pathway publication-title: For Immunopathol Dis Therap – volume: 21 start-page: 643 year: 2016 ident: 2021122508155345900_R17 article-title: FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1 publication-title: The Oncologist doi: 10.1634/theoncologist.2015-0498 – volume: 21 start-page: 634 year: 2016 ident: 2021122508155345900_R9 article-title: FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy publication-title: The Oncologist doi: 10.1634/theoncologist.2015-0507 – volume: 36 start-page: 105A issue: suppl 15 year: 2018 ident: 2021122508155345900_R65 article-title: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (chemo) with or without pembrolizumab (pembro) for patients (pts) with metastatic squamous (sq) non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.105 – volume: 106 start-page: 1 year: 2017 ident: 2021122508155345900_R120 article-title: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.01.013 – volume: 26 start-page: 677 year: 2008 ident: 2021122508155345900_R33 article-title: PD-1 and its ligands in tolerance and immunity publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090331 – volume: 9 start-page: 499 year: 2017 ident: 2021122508155345900_R81 article-title: PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: Updated survival data publication-title: Immunotherapy doi: 10.2217/imt-2016-0150 – volume: 7 start-page: 1133 year: 2015 ident: 2021122508155345900_R91 article-title: MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer publication-title: Immunotherapy doi: 10.2217/imt.15.84 – volume: 24 start-page: 1178 year: 2018 ident: 2021122508155345900_R46 article-title: A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments publication-title: Nat Med doi: 10.1038/s41591-018-0085-8 – volume: 377 start-page: 1919 year: 2017 ident: 2021122508155345900_R76 article-title: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1709937 – volume: 480 start-page: 480 year: 2011 ident: 2021122508155345900_R1 article-title: Cancer immunotherapy comes of age publication-title: Nature doi: 10.1038/nature10673 – volume: 17 start-page: 299 year: 2016 ident: 2021122508155345900_R70 article-title: Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00544-6 – volume: 65 start-page: 315 year: 2010 ident: 2021122508155345900_R115 article-title: Ethnic differences in body composition and the associated metabolic profile: A comparative study between Asians and Caucasians publication-title: Maturitas doi: 10.1016/j.maturitas.2009.12.012 – volume: 17 start-page: 1497 year: 2016 ident: 2021122508155345900_R62 article-title: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30498-3 – volume: 77 start-page: 929 year: 2017 ident: 2021122508155345900_R13 article-title: Avelumab: First global approval publication-title: Drugs doi: 10.1007/s40265-017-0749-6 – volume: 9 start-page: 183 year: 1994 ident: 2021122508155345900_R19 article-title: The clinical experience with interleukin-2 in cancer therapy publication-title: Cancer Biother doi: 10.1089/cbr.1994.9.183 – volume: 17 start-page: 1097 year: 2017 ident: 2021122508155345900_R84 article-title: PD-L1 immunohistochemistry for non-small cell lung carcinoma: Which strategy should be adopted? publication-title: Expert Rev Mol Diagn doi: 10.1080/14737159.2017.1398083 – volume: 361 start-page: 958 year: 2009 ident: 2021122508155345900_R109 article-title: Screening for epidermal growth factor receptor mutations in lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0904554 – volume: 359 start-page: 91 year: 2018 ident: 2021122508155345900_R93 article-title: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors publication-title: Science doi: 10.1126/science.aan3706 – volume: 85 start-page: 622 year: 1993 ident: 2021122508155345900_R20 article-title: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/85.8.622 – volume: 22 start-page: 743 year: 2017 ident: 2021122508155345900_R12 article-title: FDA approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy publication-title: The Oncologist doi: 10.1634/theoncologist.2017-0087 – volume: 22 start-page: 1392 year: 2017 ident: 2021122508155345900_R16 article-title: FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-line therapy and beyond publication-title: The Oncologist doi: 10.1634/theoncologist.2017-0078 – volume: 22 start-page: 585 year: 2017 ident: 2021122508155345900_R11 article-title: FDA approval summary: Nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma publication-title: The Oncologist doi: 10.1634/theoncologist.2017-0004 – volume: 19 start-page: 813 year: 2007 ident: 2021122508155345900_R38 article-title: PD-1 and pD-1 ligands: From discovery to clinical application publication-title: Int Immunol doi: 10.1093/intimm/dxm057 – volume: 86 start-page: 1159 year: 1994 ident: 2021122508155345900_R21 article-title: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/86.15.1159 – volume: 22 start-page: 873 year: 2017 ident: 2021122508155345900_R10 article-title: FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy publication-title: The Oncologist doi: 10.1634/theoncologist.2016-0496 – volume: 3 start-page: 1 year: 1910 ident: 2021122508155345900_R18 article-title: The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus) publication-title: Proc R Soc Med – volume: 36 start-page: LBA4 issue: suppl 18 year: 2018 ident: 2021122508155345900_R59 article-title: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: Open-label, phase 3 KEYNOTE-042 study publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.18_suppl.LBA4 – volume: 276 start-page: 80 year: 2017 ident: 2021122508155345900_R101 article-title: LAG3 (CD223) as a cancer immunotherapy target publication-title: Immunol Rev doi: 10.1111/imr.12519 – volume: 376 start-page: 2415 year: 2017 ident: 2021122508155345900_R60 article-title: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1613493 – volume: 35 start-page: 2781 year: 2017 ident: 2021122508155345900_R61 article-title: Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH) publication-title: J Clin Oncol doi: 10.1200/JCO.2016.71.9476 – volume: 359 start-page: 97 year: 2017 ident: 2021122508155345900_R92 article-title: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients publication-title: Science doi: 10.1126/science.aan4236 – volume: 378 start-page: 1976 year: 2018 ident: 2021122508155345900_R74 article-title: Neoadjuvant PD-1 blockade in resectable lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1716078 – volume: 18 start-page: 31 year: 2017 ident: 2021122508155345900_R99 article-title: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30624-6 – volume: 17 start-page: 3520 year: 2011 ident: 2021122508155345900_R22 article-title: PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-3126 – volume: 328 start-page: 267 year: 1987 ident: 2021122508155345900_R4 article-title: A new member of the immunoglobulin superfamily--CTLA-4 publication-title: Nature doi: 10.1038/328267a0 – volume: 551 start-page: 512 year: 2017 ident: 2021122508155345900_R95 article-title: Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer publication-title: Nature doi: 10.1038/nature24462 – volume: 170 start-page: 1120 year: 2017 ident: 2021122508155345900_R68 article-title: Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade publication-title: Cell doi: 10.1016/j.cell.2017.07.024 – volume: 342 start-page: 1432 year: 2013 ident: 2021122508155345900_R23 article-title: Breakthrough of the year 2013 publication-title: Cancer immunotherapy. Science – volume: 209 start-page: 1201 year: 2012 ident: 2021122508155345900_R36 article-title: Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 publication-title: J Exp Med doi: 10.1084/jem.20112741 – volume: 5 start-page: e1213934 year: 2016 ident: 2021122508155345900_R83 article-title: Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1213934 – volume: 387 start-page: 1837 year: 2016 ident: 2021122508155345900_R56 article-title: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00587-0 – volume: 107 start-page: djv069 year: 2015 ident: 2021122508155345900_R2 article-title: Checkpoint blockade immunotherapy for cancer comes of age publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djv069 – volume: 22 start-page: 311 year: 2017 ident: 2021122508155345900_R14 article-title: FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis publication-title: The Oncologist doi: 10.1634/theoncologist.2016-0476 – volume: 373 start-page: 1627 year: 2015 ident: 2021122508155345900_R52 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 – volume: 35 start-page: 3924 year: 2017 ident: 2021122508155345900_R53 article-title: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) publication-title: J Clin Oncol doi: 10.1200/JCO.2017.74.3062 – volume: 169 start-page: 1130 year: 2017 ident: 2021122508155345900_R44 article-title: Interferon-γ drives Treg fragility to promote anti-tumor immunity publication-title: Cell doi: 10.1016/j.cell.2017.05.005 – volume: 378 start-page: 2078 year: 2018 ident: 2021122508155345900_R64 article-title: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1801005 – volume: 33 start-page: 2660 year: 2015 ident: 2021122508155345900_R75 article-title: Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.60.0130 – volume: 551 start-page: 517 year: 2017 ident: 2021122508155345900_R89 article-title: A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy publication-title: Nature doi: 10.1038/nature24473 – volume: 378 start-page: 2093 year: 2018 ident: 2021122508155345900_R69 article-title: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden publication-title: N Engl J Med doi: 10.1056/NEJMoa1801946 – volume: 11 start-page: 3887 year: 1992 ident: 2021122508155345900_R30 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 192 start-page: 1027 year: 2000 ident: 2021122508155345900_R37 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J Exp Med doi: 10.1084/jem.192.7.1027 – volume: 7 start-page: OF2 year: 2017 ident: 2021122508155345900_R97 publication-title: Cancer Discov – volume: 9 start-page: 154 year: 2014 ident: 2021122508155345900_R111 article-title: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000033 – volume: 18 start-page: 1141 year: 2017 ident: 2021122508155345900_R15 article-title: PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30512-0 – volume: 11 start-page: S140 year: 2016 ident: 2021122508155345900_R71 article-title: 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SOC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(16)30301-X – volume: 2 start-page: 93397 year: 2017 ident: 2021122508155345900_R107 article-title: Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer publication-title: JCI Insight doi: 10.1172/jci.insight.93397 – volume: 389 start-page: 255 year: 2017 ident: 2021122508155345900_R55 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X – volume: 5 start-page: 2190 year: 2015 ident: 2021122508155345900_R42 article-title: Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients publication-title: Am J Cancer Res – volume: 8 start-page: 1162 year: 2017 ident: 2021122508155345900_R114 article-title: Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity publication-title: Front Microbiol doi: 10.3389/fmicb.2017.01162 – volume: 348 start-page: 124 year: 2015 ident: 2021122508155345900_R85 article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer publication-title: Science doi: 10.1126/science.aaa1348 – volume: 36 start-page: 758 year: 2018 ident: 2021122508155345900_R108 article-title: Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme publication-title: Nat Biotechnol doi: 10.1038/nbt.4180 – volume: 18 start-page: 1182 year: 2017 ident: 2021122508155345900_R90 article-title: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30422-9 – volume: 363 start-page: 711 year: 2010 ident: 2021122508155345900_R28 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1003466 – volume: 16 start-page: 2598 year: 2017 ident: 2021122508155345900_R87 article-title: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-17-0386 – volume: 351 start-page: 1463 year: 2016 ident: 2021122508155345900_R86 article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade publication-title: Science doi: 10.1126/science.aaf1490 – volume: 18 start-page: 13 year: 2017 ident: 2021122508155345900_R50 article-title: Immunotherapy comes of age in lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2016.06.006 – volume: 29 start-page: 2066 year: 2011 ident: 2021122508155345900_R110 article-title: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas publication-title: J Clin Oncol doi: 10.1200/JCO.2010.32.6181 – volume: 66 start-page: 115 year: 2016 ident: 2021122508155345900_R48 article-title: Cancer statistics in China, 2015 publication-title: CA Cancer J Clin doi: 10.3322/caac.21338 – volume: 114 start-page: 4993 year: 2017 ident: 2021122508155345900_R121 article-title: Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1705327114 – volume: 10 start-page: 93 year: 2018 ident: 2021122508155345900_R63 article-title: Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer publication-title: Immunotherapy doi: 10.2217/imt-2017-0121 – volume: 17 start-page: 232 year: 2016 ident: 2021122508155345900_R72 article-title: A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: Rationale and protocol design of the ARCTIC study publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2016.03.003 – volume: 36 start-page: LBA9000 issue: suppl 18 year: 2018 ident: 2021122508155345900_R66 article-title: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.18_suppl.LBA9000 |
| SSID | ssj0015932 |
| Score | 2.65934 |
| SecondaryResourceType | review_article |
| Snippet | The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies... This article summarizes the latest clinical applications of PD‐1/PD‐L1 blockade therapy in advanced non‐small cell lung cancer (NSCLC) worldwide and in China,... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S31 |
| SubjectTerms | Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - immunology China Clinical trials Clinical Trials as Topic Combination therapy Humans Immune checkpoint inhibitors Immunotherapy - methods Lung Cancer Lung Neoplasms - drug therapy Lung Neoplasms - immunology Non‐small‐cell lung cancer PD‐1/PD‐L1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Randomized Controlled Trials as Topic |
| Title | PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2019-IO-S1-s05 https://www.ncbi.nlm.nih.gov/pubmed/30819829 https://www.proquest.com/docview/2187513854 https://pubmed.ncbi.nlm.nih.gov/PMC6394772 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Pb9MwFLfKkCYuiP8r_2Sk3VC2OLGTBrhAy7ShrpnUTpRT5DguK5R0Ys0BTnwEPiN3vgPvOU6aqhNa4ZI0rp24eb--9_z88zMhu5g0TDA9cVLJPYdnQjmSa9cJhdTaCzVXKcY7jgfB4Sl_NxbjVut3g7VULNI99f3SdSX_IlUoA7niKtkNJFvfFArgM8gXjiBhOF5Jxie9mquACqlx2WfP34CZ-iwzjaQKTBxgIhvVjP8APL6q7vCLnM3qqy4G8_oFsgGwqtlFskrihJ5pUSZ1PjC5SCqNWcX8Pi2xN89NPmxAETqxPfnN8vTjs-m8EX4Yl2Td_hTDLR9retC0MLahAFU1Xxa_t8HtD5W9teEKXCG1Qv24hA-0Rvpk4BY6IbOZwrVVzBx3w3PHTc1drr62CB2yhh4eWtNSmvRhmVtrzVoEPgfh4IrR-pXsmT4fxc6QOReuWFrJihlQtxObtDQOQzzoxswLA_caue7BqAbV8ige15NeIvLLyXn787fJrn3a_t-etOpRrQ2T1tm-zVGYcaNGt8hNO_6hr0sw3yYtnd8h28eW4XGXnJ_0fv34yfbNqc9ohWJqUUynOa1QTAHFUMvgF86IXIrIpSVyX1CLW1rilgJuaYlbusTtPXJ68HbUPXTsriCOEkh_VRl4xTJTyvUkWMcs0FKzCEtkoIVS8BaZkFngT7iOfJGCERPK7ehJipRMj_v3yVY-z_UOoVkaeGkUpGnoSq4y8EF4BJ6cyjrg12edqE1eVm82UTZlPu7cMktw6AxySVbkkqBckqM4GbIE5NImom59XqaOuWK7Z5UQE9D1OIEncz0vLhJwx0PB_I7gbfKgFGp9Zx99-44HfQ5XxF1XwDzyq9_k0zOTTx4GKRzg2CavDDA26mxSg_rh_zV_RG4s1cVjsrX4Wugn4O8v0qfmX_IH4SsAKQ |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PD%E2%80%901%2FPD%E2%80%90L1+Blockade+Therapy+in+Advanced+Non%E2%80%90Small%E2%80%90Cell+Lung+Cancer%3A+Current+Status+and+Future+Directions&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Xia%2C+Liliang&rft.au=Liu%2C+Yuanyong&rft.au=Wang%2C+Ying&rft.date=2019-02-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1083-7159&rft.eissn=1549-490X&rft.volume=24&rft.issue=S1&rft.spage=S31&rft.epage=S41&rft_id=info:doi/10.1634%2Ftheoncologist.2019-IO-S1-s05&rft.externalDBID=10.1634%252Ftheoncologist.2019-IO-S1-s05&rft.externalDocID=ONCO12760 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |